Merck Continues Pursuit Of Cardiovascular Candidates With Theravance Partnership
This article was originally published in The Pink Sheet Daily
The New Jersey-based big pharma continues to take shots on the cardiovascular goal, even after a string of failures in the space.
You may also be interested in...
Merck’s recent sale of its consume health business to Bayer involved a side bet on a new class of antihypertensive, which could mark a return to cardiovascular for Merck.
Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.
With largely positive results from four of seven Phase III studies, GlaxoSmithKline and Theravance say they are on track for filing their LABA/LAMA combination UMEC/VI at the end of 2012. But some analysts are wary about regulatory prospects for any LABA-containing drugs and say concerns about dosing could trip up U.S. filing.